Diabetic Foot News and Research

RSS

Cardium announced that patients enrolled for MATRIX clinical trail have completed their evaluation period

Cardium Therapeutics (NYSE Amex: CXM) today announced that all patients enrolled in the Company's MATRIX clinical study have now completed their initial 12-week evaluation period and that it plans to provide detailed safety and efficacy data in late September 2009.

26 Aug 2009

Study reveals safety of ConvaTec's advanced antimicrobial dressing

ConvaTec, a world-leading provider of innovative medical technologies for community and hospital care, today announced new data showing that AQUACEL(R) Ag, the company's advanced antimicrobial dressing, is safe for use in an MRI environment.

25 Aug 2009

A new startup at California Nanosystems Institute

UCLA's newly launched on-campus technology incubator at the California NanoSystems Institute (CNSI) has opened lab space to MediSens Wireless, a startup company that develops and manufactures personal body-monitoring systems for medical and health applications.

6 Aug 2009

Oxygen therapy may prevent diabetics losing limbs

Researchers say on a daily basis around 275 Australians develop type 2 diabetes and worldwide, every 30 seconds a person somewhere has a lower limb amputated because of diabetic foot disease.

16 Jul 2009

Collagen bioscaffolds used to treat diabetic ulcers, save limbs

San Diego surgeons report that they have been successfully utilizing a collagen bioscaffold material developed by Irvine-based Pegasus Biologics, Inc. to complement soft tissue repair and regeneration among high risk wound patients.

22 Apr 2009

Human foetal stem cells can effectively be used to treat back leg ischaemic ulcers

Treatment of chronic wounds is a continuing clinical problem and socio-economic burden with diabetic foot ulcers alone costing the NHS £300 million a year.

20 Apr 2009

Scientists hope European grant can improve healthy ageing

Researchers hope to achieve healthy ageing by enhancing body healing capacity and reducing chronic inflammation.

1 Dec 2008

FDA issues complete response letter for Ceftobiprole for treatment of complicated skin infections

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), today announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

26 Nov 2008

Discovery of new mechanism that regulates formation of blood vessels

Researchers in one of the external groups of the Instituto Gulbenkian de Ciencia (IGC), in Portugal, have discovered a novel mechanism which regulates the process whereby new blood vessels are formed and wounds heal, including chronic wounds, such as those found in diabetic patients and those suffering from morbid obesity.

17 Nov 2008

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

NanoVibronix receives FDA clearance for PainShield diathermy device

NanoVibronix, a medical device company, announced that the US Food and Drug Administration (FDA) has granted 510K clearance to market PainShield MD, a diathermy device used to treat pain. PainShield is the first hands-free, patch-based diathermy device, thus allowing for an entirely new dimension in ultrasound treatment of pain and soft tissue healing. The PainShield consists of a disposable patch connected to a portable reusable driver and generates ultrasound waves to the desired area of the body.

23 Oct 2008

People with diabetes lose more than money

It is not about money. No amount of money will give back my limb" said a 65 years old woman with diabetes (name withheld on request) who underwent limb amputation at the Gandhi Memorial & Associated Hospitals (GM & AH).

7 Oct 2008

Cancer warning on diabetic ulcer gel

The U.S. watchdog the Food and Drug Administration (FDA) says a warning will be added to the label of a topical gel used to treat leg and foot ulcers which refuse to heal in diabetic patients.

9 Jun 2008

FDA announces label changes for Regranex - boxed warning

The U.S. Food and Drug Administration has announced the addition of a boxed warning to the label of Regranex Gel 0.01% (becaplermin) to address the increased risk of cancer mortality in patients who use 3 or more tubes of the product. Regranex is a topical cream indicated for the treatment of leg and foot ulcers that are not healing in diabetic patients.

8 Jun 2008

MacroChem acquires Virium Pharmaceuticals

MacroChem Corporation announced today that on April 18, 2008 it acquired Virium Pharmaceuticals Inc., a non-public, development stage company developing and commercializing novel therapeutics, with a portfolio of clinical stage product candidates focused in oncology, including its next generation nucleoside analogue licensed from the Southern Research Institute.

23 Apr 2008

FDA sends approvable letter for Ceftobiprole as treatment of complicated skin infections

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), has announced that it received an approvable letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections.

19 Mar 2008

Peptoids as new class of antibiotic drugs

Drug-resistant bacterial infections are a growing concern, and much research has been devoted to finding new classes of antibiotics to fight them.

10 Mar 2008

A look at China's most innovative health biotechnology companies

Government funds innovation but venture capital needed; Wary investors 'need to be shown the exits'; Returning 'sea turtles' bring expertise, international credibility

8 Jan 2008

More than six out of ten people with diabetes are walking around in the wrong-sized shoes

More than six out of ten people with diabetes are walking around in the wrong-sized shoes, exposing themselves to serious foot problems that could lead to amputation, according to research in the November issue of IJCP, the International Journal of Clinical Practice.

14 Nov 2007

Charcot foot becoming more common

Charcot foot is a sudden softening of the foot's bones caused by severe neuropathy, or nerve damage, a common diabetic foot complication. It can trigger an avalanche of problems, including joint loss, fractures, collapse of the arch, massive deformity, ulcers, amputation, and even death. As the disorder progresses, the bottom of the foot can become convex, bulging like the hull of a ship.

24 Oct 2007